11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
- Resource Type
- Abstract
- Source
- In
Journal of Thoracic Oncology April 2023 18(4) Supplement:S43-S44 - Subject
- Language
- ISSN
- 1556-0864